欧盟EMA药品数据库-欧盟集中审批药品（European Medicines Agency Authorisation of Medicines DataBase）

商品名称	适用类别	通用名称	活性成分	产品号	上市许可开发者/申请人/持有人	上市许可日期	许可状态
Eltrombopag Viatris	Human	eltrombopag	eltrombopag olamine	EMEA/H/C/006417	Viatris Limited	2024/12/12	Authorised
Theralugand	Human	lutetium (177Lu) chloride	lutetium (177Lu) chloride	EMEA/H/C/005882	Eckert & Ziegler Radiopharma GmbH	2024/11/22	Authorised
Hympavzi	Human	marstacimab	marstacimab	EMEA/H/C/006240	Pfizer Europe MA EEIG	2024/11/18	Authorised
Flucelvax	Human	influenza vaccine (surface antigen, inactivated, prepared in cell cultures)	A/Wisconsin/67/2022 (H1N1)pdm09-like strain (A/Georgia/12/2022 CVR-167) / A/District of Columbia/27/2023 (H3N2)-like strain (A/Victoria/800/2024 CVR-289) / B/Austria/1359417/2021-like strain (B/Singapore/WUH4618/2021)	EMEA/H/C/006532	Seqirus Netherlands B.V.	2024/11/15	Authorised
Fluad	Human	influenza vaccine (surface antigen, inactivated, adjuvanted)	type A (H1N1) strain; type A (H3N2) strain; type B strain;A/Victoria/4897/2022 (H1N1)pdm09 like strain (A/Victoria/4897/2022, IVR-238);A/Croatia/10136RV/2023 (H3N2)-like strain (A/Croatia/10136RV/2023, X-425A);B/Austria/1359417/2021 like strain (B/Austria/1359417/2021, BVR-26)	EMEA/H/C/006538	Seqirus Netherlands B.V.	2024/11/15	Authorised
Elahere	Human	mirvetuximab soravtansine	mirvetuximab soravtansine	EMEA/H/C/005036	AbbVie Deutschland GmbH & Co. KG	2024/11/14	Authorised
Penbraya	Human	meningococcal groups A, C, W, Y conjugate and group B vaccine (recombinant, adsorbed)	Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group W polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group B fHBP protein subfamily A;Neisseria meningitidis group B fHBP protein subfamily B	EMEA/H/C/006165	Pfizer Europe MA EEIG	2024/11/14	Withdrawn
Pomalidomide Teva	Human	pomalidomide	Pomalidomide	EMEA/H/C/006302	Teva GmbH	2024/11/14	Authorised
Afqlir	Human	aflibercept	aflibercept	EMEA/H/C/006150	Sandoz GmbH	2024/11/13	Authorised
Opuviz	Human	aflibercept	aflibercept	EMEA/H/C/006056	Samsung Bioepis NL B.V.	2024/11/13	Authorised
Yuvanci	Human	macitentan;tadalafil	macitentan;tadalafil	EMEA/H/C/005001	Janssen-Cilag International NV	2024/09/27	Authorised
Otulfi	Human	ustekinumab	ustekinumab	EMEA/H/C/006544	Fresenius Kabi Deutschland GmbH	2024/09/25	Authorised
Fymskina	Human	ustekinumab	ustekinumab	EMEA/H/C/005805	Formycon AG	2024/09/25	Authorised
Epruvy (previously Ranibizumab Midas)	Human	ranibizumab	ranibizumab	EMEA/H/C/006528	Midas Pharma GmbH	2024/09/19	Authorised
Tuznue	Human	trastuzumab	trastuzumab	EMEA/H/C/006252	Prestige Biopharma Belgium	2024/09/19	Authorised
Anzupgo	Human	delgocitinib	Delgocitinib	EMEA/H/C/006109	LEO Pharma A/S	2024/09/19	Authorised
Axitinib Accord	Human	axitinib	axitinib	EMEA/H/C/006206	Accord Healthcare S.L.U.	2024/09/19	Authorised
Loqtorzi	Human	toripalimab	toripalimab	EMEA/H/C/006120	Topalliance Biosciences Europe Limited	2024/09/19	Authorised
Vyloy	Human	zolbetuximab	zolbetuximab	EMEA/H/C/005868	Astellas Pharma Europe B.V.	2024/09/19	Authorised
Iqirvo	Human	elafibranor	Elafibranor	EMEA/H/C/006231	Ipsen Pharma	2024/09/19	Authorised

商品名称Name of medicine	*示例：Zokinvy（英文）
药品通用名或非专利名称International non-proprietary name (INN) / common name	*示例：lonafarnib（英文）
活性成分Active substance	*示例：lonafarnib（英文）
产品号EMA product number	*示例：EMEA/H/C/005271
ATC编号ATC code	*示例：L01EA06
上市许可开发者/申请人/持有人Marketing authorisation developer / applicant / holder	*示例：Janssen
药物治疗学分组Pharmacotherapeutic group	*示例：Antineoplastic
适应症Therapeutic indication	*示例：leukaemia
许可状态Medicine status
上市许可日期Marketing authorisation date	-